The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

Merck’s interest in SpringWorks — and its purchase of Yale spinout Modifi Biosciences this fall — are signs that Connecticut’s pharma cluster is maturing and growing even in an uncertain ...